News headlines about GenMark Diagnostics (NASDAQ:GNMK) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. GenMark Diagnostics earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 46.8716057145379 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

GenMark Diagnostics (GNMK) opened at $5.87 on Friday. GenMark Diagnostics has a fifty-two week low of $3.63 and a fifty-two week high of $13.67. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.97 and a quick ratio of 2.77. The firm has a market cap of $320.55, a price-to-earnings ratio of -4.81 and a beta of 0.65.

GenMark Diagnostics (NASDAQ:GNMK) last posted its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The business had revenue of $11.60 million during the quarter, compared to analysts’ expectations of $14.56 million. GenMark Diagnostics had a negative net margin of 116.76% and a negative return on equity of 100.33%. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period last year, the business posted ($0.27) earnings per share. research analysts predict that GenMark Diagnostics will post -1.18 EPS for the current year.

GNMK has been the subject of a number of recent research reports. Zacks Investment Research raised shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a report on Monday, December 11th. BTIG Research set a $11.00 target price on shares of GenMark Diagnostics and gave the company a “buy” rating in a report on Monday, November 20th. Cowen reissued a “buy” rating and issued a $10.00 target price on shares of GenMark Diagnostics in a report on Friday, November 3rd. Canaccord Genuity reissued a “buy” rating and issued a $14.00 target price on shares of GenMark Diagnostics in a report on Monday, October 30th. Finally, Needham & Company LLC cut their target price on shares of GenMark Diagnostics from $15.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $11.80.

In related news, insider Hany Massarany sold 8,252 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $4.74, for a total value of $39,114.48. Following the completion of the sale, the insider now directly owns 362,957 shares in the company, valued at $1,720,416.18. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Michael Kagnoff purchased 20,000 shares of the stock in a transaction that occurred on Monday, November 6th. The stock was bought at an average price of $4.13 per share, with a total value of $82,600.00. Following the completion of the transaction, the director now owns 64,413 shares of the company’s stock, valued at $266,025.69. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 22,407 shares of company stock valued at $113,078. 7.50% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “GenMark Diagnostics (GNMK) Earning Somewhat Favorable Press Coverage, Report Finds” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2018/01/28/genmark-diagnostics-gnmk-earning-somewhat-favorable-press-coverage-report-finds.html.

About GenMark Diagnostics

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.